Venture Partners Vii L P So... Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture So AERI stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Aerie Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture sold 1,008,022 units of AERI stock worth $24,212,688 on 9 July 2014.

The largest trade Venture's ever made was selling 1,008,022 units of Aerie Pharmaceuticals Inc stock on 9 July 2014 worth over $24,212,688. On average, Venture trades about 1,008,022 units every 0 days since 2014.

You can see the complete history of Venture So stock trades at the bottom of the page.

Insiders trading at Aerie Pharmaceuticals Inc

Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra et Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.

What does Aerie Pharmaceuticals Inc do?

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.

Complete history of Venture So stock trades at Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc executives and stock owners

Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Vicente Anido,
  Chairman of the Board, Chief Executive Officer
• Thomas Mitro,
  President, Chief Operating Officer
• John LaRocca,
  General Counsel and Assistant Secretary
• Richard Rubino,
  Chief Financial Officer, Treasurer, Secretary
• Casey Kopczynski,
  Co-Founder, Chief Scientific Officer
• Raj Kannan,
  CEO, Principal Financial Officer & Director
• Thomas A. Mitro,
  Pres & COO
• Dr. Casey C. Kopczynski,
  Co-Founder & Chief Scientific Officer
• John W. LaRocca Esq.,
  Gen. Counsel & Sec.
• Dr. David A. Hollander M.B.A., M.D.,
  Chief R&D Officer
• Benjamin McGraw,
  Lead Independent Director
• Gerald Cagle,
  Independent Director
• Julie McHugh,
  Independent Director
• David Gryska,
  Independent Director
• Mechiel Du Toit,
  Independent Director
• Richard Croarkin,
  Independent Director
• Dr. Benjamin F. McGraw III, J.D., Pharm.D.,
  Exec. Chairman
• Peter McDonnell,
  Director
• David Hollander,
  Chief Research and Development Officer
• Nina Ohara,
  Director of Marketing
• Craig R. Skenes,
  Head of Bus. Devel.
• Marvin J. Garrett,
  Head of Regulatory Affairs & Quality Assurance
• Wanda Francies,
  Head of HR
• Jeffrey M. Calabrese CPA,
  VP of Fin. & Principal Accounting Officer
• Dr. Michelle Senchyna Ph.D.,
  Head of Clinical Devel. & Operations
• Peter F. Lang,
  Chief Financial Officer
• Carolyn McAuliffe,
  Sr. Director of Communications
• Evan Hockman,
  VP of Sales
• Tad Heitmann,
  Head of Communications
• Andrew Allen,
  Chief Compliance Officer
• Ami Bavishi,
  Director of Investor Relations
• Jeffrey Calabrese,
  Director of Accounting
• Toit Michael Du,
  Director
• Murray A Goldberg,
  Director
• Capital Management Ii, Llc ...,
  
• Geoffrey M Duyk,
  Director
• Capital Management Ii, Llc ...,
  
• Capital Management Ii, Llc ...,
  
• James E Deerfield Mgmt L.P....,
  
• Anand Healy Jamespowell Mic...,
  
• James V Mazzo,
  Director
• Group Holdings (Sbs) Adviso...,
  
• Brian Levy,
  Chief Medical Officer
• Venture Partners Vii L P So...,
  
• Iv, L.P.Acmp Iv Llcjanney D...,
  
• Lifesciences Ii, L.P.Clarus...,
  
• Iv, L.P.Janney Danielnohra ...,
  
• Anand Mehra,
  Director
• Peter Frederick Lang,
  Chief Financial Officer
• Capital Management Iv, Llc ...,
  
• Capital Management Ii, Llc ...,
  
• Jeffrey Calabrese,
  Vice President of Finance
• Christopher Staten,
  Interim CFO
• Raj Kannan,
  Chief Executive Officer
• Kathleen Mcginley,
  CHRO & VP, Corp Services